First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F08%3A00001199" target="_blank" >RIV/00179906:_____/08:00001199 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/08:00107075
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma
Original language description
Described the effect reduced dose interferon-alpha 2a with bevacizumab in patients with metastatic cell carcinoma.
Czech name
Kombinace bevacizumabu s dávkami interferonu-alfa 2a u pacientů s karcinomem ledvin
Czech description
Popsán efekt redukce dávky interferonu na účinnost v kombinaci s bevacizumabem u karcinomu ledvin.
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2008
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of Oncology
ISSN
0923-7534
e-ISSN
—
Volume of the periodical
19
Issue of the periodical within the volume
8
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
—
UT code for WoS article
000258136800017
EID of the result in the Scopus database
—